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BACKGROUND
The management of urinary stone disease is determined by several factors, including stone composition, location, duration, size, recurrence status, the presence of other complications, and severity of disease. Prevalence in the general population is approximately 2% to 3%, and the proportion of stones found in the ureter is approximately 20%. 1, 2 Guidelines note that 95% of stones smaller than 4 mm pass spontaneously in an average of 40 days, however slightly less than 50% of stones larger than 5 mm pass unassisted. 3 The primary objective of therapy is stone removal, either by expulsion, shock wave lithotripsy (SWL), or ureteroscopy. More invasive therapies carry greater expense and risk (ie, renal colic, urinary tract infection, regrowth of residual fragments), making medical expulsion therapy (MET) an important alternative in patients where active removal is not indicated. MET with agents such as alpha blockers and nifedipine has been shown to accelerate spontaneous clearance of ureteral calculi, with or without adjunctive SWL, and decrease renal colic. [2] [3] [4] Tamsulosin is a selective alpha-1 receptor antagonist; the action of alpha blockers on ureteral smooth muscle dilatates the lumen and inhibits spasms, especially in the distal part of the ureter.
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PATIENT POPULATION
Adults with symptomatic distal ureteral tract stones less than 10 mm or who are not candidates for active stone removal.
DOSAGE AND DURATION
Oral tamsulosin 0.4 mg daily, usually at bedtime, for 7 to 42 days or until expulsion of stones. Tamsulosin has also been used as adjunctive therapy to shock wave and laser lithotripsy.
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RESULTS
The use of alpha-1 blockers, including tamsulosin, for treating ureteral stones is recommended by US and European guidelines and is supported by data from meta-analyses as well as numerous controlled trials. Tamsulosin has been studied in trials enrolling more than 600 total patients and has been shown to be effective in facilitating ureteral stone expulsion as medical therapy alone as well as an adjunct to SWL and ureteroscopy. Some trials indicate a class effect of alpha-1 blockers with tamsulosin reported to be equally effective as terazosin, doxazosin, and alfuzosin.
Guidelines
American Urological Association (AUA) and European Association of Urology (EAU) Guidelines for Management of Ureteral Calculi
The AUA and EAU guidelines for the management of ureteral calculi, and the updated EAU guidelines, indicate that medical expulsive therapy can effectively accelerate the spontaneous passage of ureteral stones as well as stone fragments generated via SWL and limit pain thereby reducing analgesic requirements (Level of Evidence: 1a). In a meta-analysis performed for the guidelines, patients receiving alpha blockers Volume 50, January 2015
Off-Label Drug Uses or nifedipine were more likely to pass their stones compared with controls. Tamsulosin was the most commonly studied alpha blocker and a class effect was demonstrated by several trials showing effective stone expulsion with terazosin, doxazosin, alfuzosin, naftopidil, and silodosin. Tamsulosin was also shown to be significantly better than nifedipine in facilitating stone expulsion and relieving colic. Alpha blockers were recommended by the guidelines for MET (Level 1a; Grade A).
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Controlled Trials
In a prospective, multicenter trial, 3,189 adult outpatients with distal ureteric stones (4 to 7 mm) and renal colic were randomized to receive either tamsulosin (0.4 mg daily) or nifedipine (10 mg thrice daily) until expulsion. All patients were encouraged to maintain water intake between 2 and 2.5 L daily and levofloxacin therapy (200 mg twice daily). Pain relief with dicoflenac suppositories was monitored (50 mg). The median age was 30.7 years in the tamsulosin group and 34.5 years in the nifedipine group. There was no difference between the 2 groups for mean stone size (5.8 mm vs 5.6 mm). The primary endpoint, overall stone expulsion rate at 4 weeks, was significantly higher in the tamsulosin group when compared to the nifedipine group (95.86% vs 73.51%; P < .01). Secondary outcomes, including mean expulsion time (78.35 vs 137.93 hours; P < .01) and mean consumption of diclofenac (52.35 mg vs 109.33 mg; P < .01) were also significantly less in the tamsulosin group. There was no difference between the 2 groups for incidence of side effects (5.62% vs 6.16%; P > .05).
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Other
A meta-analysis of randomized controlled trials that evaluated tamsulosin for treatment of either upper or lower ureteral stones compared with either standard therapy or placebo identified 20 studies that met the inclusion criteria. The majority (14) were high quality and the remaining 6 were low quality. Trials were published between 2002 and 2011 and included over 1,500 patients in 10 countries; patients presented with lower ureteral stones in 17 studies. Data pooled from all 20 studies revealed that the expulsion rate was significantly higher in the tamsulosin group for both lower (P < .00001) and upper stones (P = .02) with a significant overall risk ratio (RR 1.51; P < .0001). Of the 7 studies (n = 555) included for analysis of expulsion time, significant differences were seen with tamsulosin for both upper and lower stones and for the overall mean difference (P < .00001 for each). Tamsulosin also significantly reduced the risk of ureteral colic and requirement of additional procedures (P = .0003 and P < .00001, respectively). Tamsulosin was associated with a significantly higher incidence of dizziness (P = .04). Significant heterogeneity was observed only for the side-effect analyses.
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SAFETY
This is a limited safety profile. Refer to package labeling for complete prescribing information (eg, warnings/precautions, adverse reactions, drug interactions).
Syncope, especially with the first dose, is a common adverse effect associated with alpha blockers. Adverse events reported in trials have been mild and included hypotension, palpitations, dizziness, retrograde ejaculation, and syncope.
THERAPY CONSIDERATIONS
The use of alpha-1 blockers, including tamsulosin, for treating ureteral stones is recommended by US and European guidelines and is supported by data from meta-analyses as well as numerous controlled trials. Tamsulosin has been shown to be effective in facilitating ureteral stone expulsion (≤10 mm) as medical therapy alone as well as an adjunct to SWL and ureteroscopy. Some trials indicate a class effect of alpha-1 blockers with tamsulosin reported to be equally effective as terazosin, doxazosin, and alfuzosin.
